Rand兰德：马拉维宫颈癌筛查方法的成本效益 发生率、病变治疗技术和风险分层方法的比较（英文版）

Background Recently-updated global g uidelines for cervical cancer screening incor porated new technologiesmost significantly, the ind usion of HPV DNA detect ion as a primary screening test-but leave many implementationdecisions at count ries'discretion. We sought to develo p recom mendations for Mlalavi as a test case since it has theseco nd-highest cervical cancer burden globally and high HiV prevalence. We incorporated upda ted e pidemiologicdata, the fullrange of ablation methods rec